本帖最后由 老马 于 2013-3-13 13:43 编辑
5 Y& l- z. {% D; R/ ]2 {+ Q/ z0 O
" D9 k q, z9 @* K健择（吉西他滨）+顺铂+阿瓦斯汀
) E8 R) i& U; {7 N: [" V- [ Gemzar +Cisplatin + Avastin
/ ?: M% \, v" K% f$ Z5 e5 @" D- k6 \4 phttp://annonc.oxfordjournals.org/content/21/9/1804.full
5 }, n6 f5 v7 _Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
j# P7 }2 G- U% c/ G7 c1 CPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
, k3 T$ K' }9 mResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. / g8 d# X& A: f, I- \% I# w! K: \
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 194)
5 A2 Y: K+ h- s* t% N* b华为网盘附件：* {6 S6 G' p* H0 U
【华为网盘】ava.JPG% Q5 K5 E4 r2 l/ _8 q9 E
|
显身卡
